<DOC>
	<DOCNO>NCT00716716</DOCNO>
	<brief_summary>The primary objective study assess safety FIXFc dose range 1 100 IU/kg .</brief_summary>
	<brief_title>Phase I/IIa Study FIXFc Hemophilia B Patients</brief_title>
	<detailed_description>This study previously post Syntonix Pharmaceuticals , Inc . In January , 2007 , sponsorship trial transfer Biogen Idec .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Key 1 . Are previously treat ( PTPs ) severe ( &lt; 2 IU/dL endogenous FIX level ) hemophilia B least 150 prior document exposure day FIX product . 2 . Have prior history currently detectable inhibitor define &gt; 0.6 Bethesda unit local lab . A family history inhibitor exclude patient . 3 . No prior history allergic reaction anaphylaxis associate FIX IVIG administration . 4 . No concurrent autoimmune disease . 5 . At least 7 day since last dose FIX ( washout period ) . 6 . Certain laboratory test criterion protocoldefined criterion may apply . 7 . HIV negative HIV positive CD4 count â‰¥ 200 cells/mm3 . HIV patient allow receive protease inhibitor per discretion Investigator . Key 1 . Presence major bleed episode Day 1 study . 2 . Any coagulation disorder addition hemophilia B . 3 . A patient currently dose regimen FIX would preclude participation study due possible increase risk bleed requirement withhold treatment study period . 4 . A positive ddimer screening . 5 . Documented history liver cirrhosis . 6 . Positive HBsAg and/or positive hepatitis C antibody , and/or HIV positive ALT AST great 5 time upper limit normal . 7 . Certain prior illness protocoldefined criterion . NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hemophilia B severe , previously treat patient</keyword>
</DOC>